Retatrutide Shows Superior Results to Ozempic in Recent Trial | Retatrutide News

Eli Lilly's Retatrutide outperformed Novo Nordisk's Ozempic in a recent clinical trial. This positions Retatrutide as a potentially more effective GLP-1...
Clinical Trials · November 3, 2026